Dr Reddy's Labs Q1 Results: Net profit rises just 1.4% YoY to ₹1,409 crore; revenue surges 11%
The pharma major's revenue from operations in the June-ended quarter stood at ₹ 8,572 crore, up 11.3 per cent from ₹ 7,696 crore in the corresponding quarter of the last financial year.
In terms of segment-wise performance, revenue from Global Generics, which constitutes nearly 90 per cent of the total revenue, stood at ₹ 7,562 crore compared to ₹ 6,885crore. The company posted ₹ 970 crore revenue from Pharmaceutical Services and Active Ingredients in Q1FY26, compared to ₹ 1,030 crore.
The total expenses rose 15.8 per cent at ₹ 6,957 crore in the April to June quarter for the fiscal year 2025-26 from ₹ 6,006 crore in the same quarter previous year.
The pharma company's EBITDA was ₹ 2,278 crore, accounting for approximately 26.7% of total revenues.
Partnership with Alvotech to co-develop, manufacture and co-commercialise pembrolizumab, a biosimilar candidate to Keytruda.
Collaboration with Sanofi to launch Beyfortus (Nirsevimab), a drug for preventing Respiratory Syncytial Virus (RSV) in India.
• Launched Sensimune in India, an immunotherapy product for house dust mite-induced allergies in partnership with ALK-Abell6.
Speaking on the results and the upcoming course of action, Co-Chairman & MD, G V Prasad said, 'the pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Dr Reddy's Labs, Lupin: Nifty Pharma slips 2% amid Trump tariff jitters
Pharmaceutical stocks were under selling pressure on Thursday, July 31, 2025, after US President Donald Trump announced a sweeping 25 per cent tariff on all Indian goods. Nifty Pharma slipped 1.5 per cent in trade, logging a day's low at 22,724.7. Last checked, out of 20 stocks on the Nifty Pharma index, 16 declined. Among others, Natco Pharma fell 1.7 per cent, Dr Reddy's Laboratories 1.5 per cent, Lupin 1.3 per cent, Ipca Laboratories 1.3 per cent, Zydus Lifesciences 1.2 per cent, and Granules India 1.2 per cent. India exported over $10 billion in generic drugs and Active Pharmaceutical Ingredients (APIs) to the US in FY25, according to reports. The 25 per cent tariffs on Indian goods threaten to disrupt nearly $129 billion in annual bilateral trade. The tariff order was posted by Trump on Truth Social on July 30, 2025, just days after the fifth round of trade talks concluded in Washington. He hinted at additional penalties related to India's purchases of Russian defence and energy supplies. The sixth round of negotiations is scheduled for late August 2025, with a US delegation visiting New Delhi starting August 25. Earlier in July, Trump had said that he could announce tariffs on pharmaceuticals by the end of July, which could go as high as 200 per cent. The new tariffs were supposed to be a part of a broader 'reciprocal' trade framework scheduled for implementation on August 1, Bloomberg reported. Speaking to reporters after returning from Pittsburgh, Trump said, 'Probably at the end of the month, and we're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff.' Trump imposes reciprocal tariffs In April, Trump announced sweeping reciprocal tariffs on more than 100 countries, aiming to incentivise companies to bring manufacturing back to the US. Until recently, pharmaceutical imports had largely been spared from such measures due to their critical nature. But in April, Trump warned of a 25 per cent levy on pharma imports, asserting that the move would reduce US dependence on foreign suppliers such as India and China.
New Indian Express
2 days ago
- New Indian Express
Indian equity market tumbles after Trump imposes 25% tariff on exports
CHENNAI: Indian equity markets opened sharply lower on Thursday, July 31, following the announcement of a 25 percent tariff on Indian exports by US President Donald Trump. The BSE Sensex fell 601.06 points or 0.74 percent to 80,880.80 as of 9:19 am, after opening at 80,695.50. The NSE Nifty 50 also declined significantly, shedding 175.25 points or 0.71 percent to 24,679.80, slipping below the key 24,700 mark in early trade. The gap-down opening was largely anticipated after Trump's surprise tariff decision, which also included a warning of further penalties tied to India's continued oil trade with Russia. The announcement rattled investor sentiment and triggered a broad sell-off across sectors. Analysts noted that export-oriented industries such as textiles, pharmaceuticals, auto components, and gems and jewellery are likely to bear the brunt of the new trade barriers. Within the first 15 minutes of trade, domestic markets lost over ₹5.5 lakh crore in market capitalisation. All 16 sectoral indices were trading in the red, with the small-cap and mid-cap segments each down by more than 1.25 percent. Among the major Nifty 50 laggards were Dr Reddy's Laboratories, Reliance Industries, Bharti Airtel, Mahindra & Mahindra, and Titan Company. On the other hand, a few stocks such as Jio Financial, SBI Life, and Tata Steel managed to hold gains. The Indian rupee also came under pressure, opening at around 87.69 against the US dollar—close to its all-time low—amid fears of a prolonged trade rift. Currency traders now expect the Reserve Bank of India to step in to prevent excessive volatility. Foreign institutional investors have already pulled out nearly $2 billion from Indian equities this month, including $425 million just two days earlier, exacerbating the rupee's weakness. Market experts believe the tariff move is part of a larger negotiation strategy, and many still expect a resolution to be worked out in view of the long-term strategic alignment between the US and India. However, the near-term market outlook remains cautious, with investors awaiting further clarity on trade developments and their possible impact on earnings. Technical analysts see immediate support for the Nifty around 24,600–24,750, while resistance is expected near the 25,000–25,200 zone. The Sensex, similarly, may find support closer to the 80,000 mark. Broader sentiment remains fragile, and unless there is a swift diplomatic or policy response, markets may continue to trade with a negative bias in the short term.
Mint
3 days ago
- Mint
US layoffs: This pharma firm to cut jobs amid $3 billion cost-reduction plan. Here's what we know
US pharmaceutical company Merck announced on Tuesday that it would cut jobs as part of a cost-reduction plan aimed at saving $3 billion annually by 2027. 'The Company approved a new restructuring program, in which it expects to eliminate certain administrative, sales and R&D positions,' reported AFP, citing a company statement. Merck also lowered its revenue forecast for 2025 slightly. The company did not specify how many posts would be affected, but mentioned that it would continue to hire employees 'into new roles across strategic growth areas of the business.' The plan involves Merck decreasing its "global real estate footprint" and further optimising its manufacturing network. The announcement followed Washington's declaration on Sunday of a trade agreement with the European Union, which established a 15 per cent tariff on most EU imports into the US, including pharmaceuticals. US President Donald Trump previously threatened a 200 per cent tariff on pharmaceuticals, and an investigation into these levies is currently underway. Merck's revenue for the second quarter was $15.8 billion, a 2% decline year-on-year. However, it surpassed Factset's consensus expectations. The company experienced a drop in sales of its HPV vaccine Gardasil. The vaccine generated $1.1 billion in the second quarter, a 55% decrease year-on-year, due to waning demand in China and increased competition from generic drugs in international markets. In contrast, sales of the cancer drug Keytruda, a major player in oncology, rose 9% to nearly $8 billion between April and the end of June. Merck is cutting $3 billion from its annual budget in anticipation of off-brand competition to its top-selling cancer drug, Keytruda. The company announced that it intends to reinvest these savings into the development and launch of new medicines, reported Bloomberg. The company has lost over 30% of its value in the past 12 months amid growing investor concern about its future after Keytruda.
